[6] By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related dementias and cognitive aging.
[7][8][9] The ADDF has invested nearly $65 million to fund some 450 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.
Through PACT, the ADDF is funding a number of "repurposing"[18] clinical trials, whereby drugs developed for other indications (e.g., diabetes) are tested for their effectiveness in Alzheimer's disease.
Because these drugs have already passed significant safety tests, the risk of failure is reduced and, if pharmaceuticals are found to be effective in Alzheimer's patients, they can be brought more rapidly to market.
Resources include: Every year, the ADDF hosts a series of events to raise awareness and funds to support Alzheimer's research and drug development.